1. Home
  2. DFTX vs LILAK Comparison

DFTX vs LILAK Comparison

Compare DFTX & LILAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$21.98

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Logo Liberty Latin America Ltd. Class C

LILAK

Liberty Latin America Ltd. Class C

HOLD

Current Price

$8.27

Market Cap

1.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFTX
LILAK
Founded
N/A
2017
Country
United States
Bermuda
Employees
N/A
9000
Industry
Cable & Other Pay Television Services
Sector
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DFTX
LILAK
Price
$21.98
$8.27
Analyst Decision
Strong Buy
Hold
Analyst Count
5
1
Target Price
$42.00
$8.20
AVG Volume (30 Days)
1.6M
790.9K
Earning Date
05-04-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.37
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.62
$4.23
52 Week High
$22.72
$9.13

Technical Indicators

Market Signals
Indicator
DFTX
LILAK
Relative Strength Index (RSI) 67.43 48.27
Support Level $16.41 $7.58
Resistance Level N/A $8.53
Average True Range (ATR) 1.08 0.35
MACD 0.26 -0.04
Stochastic Oscillator 79.19 38.43

Price Performance

Historical Comparison
DFTX
LILAK

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

About LILAK Liberty Latin America Ltd. Class C

Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.

Share on Social Networks: